General mean age of diagnosis of the three main clinical MEN1 manifestation in our patients was about 15 years (reaching up to 20 years in case of gastrinomas) earlier than sporadic counterparts; due to natural characteristics of MEN1 but also favoured by the periodic tumour-surveillance screening program and constant follow-up of all MEN1 affected patients and mutation carriers. This evidence concerns the gene MEN1 and gastrin-producing neuroendocrine tumor.